STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focused on targeted protein degradation, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Chief Medical Officer Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer Andrew Saik will engage in a fireside chat on Tuesday, December 3 at 2:30 p.m. ET in New York. The presentation will be accessible via live audio webcast on the company's website under the Events and Presentations section.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer and Andrew Saik, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 2:30 p.m. ET in New York.

A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com


FAQ

When is Arvinas (ARVN) presenting at the Piper Sandler Healthcare Conference?

Arvinas (ARVN) is presenting at the Piper Sandler Healthcare Conference on Tuesday, December 3 at 2:30 p.m. ET in New York.

Who will represent Arvinas (ARVN) at the Piper Sandler Healthcare Conference?

Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will represent Arvinas at the conference.

How can investors watch Arvinas's (ARVN) presentation at the Piper Sandler Conference?

Investors can watch the presentation through a live audio webcast available on Arvinas's website under the Events and Presentations section.

What type of company is Arvinas (ARVN)?

Arvinas is a clinical-stage biotechnology company that develops drugs based on targeted protein degradation.
Arvinas

NASDAQ:ARVN

ARVN Rankings

ARVN Latest News

ARVN Latest SEC Filings

ARVN Stock Data

748.86M
59.11M
6.85%
94.18%
11.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN